Adrenocortical Carcinoma Xenograft in Zebrafish Embryos as a Model To Study the In Vivo Cytotoxicity of Abiraterone Acetate.


Journal

Endocrinology
ISSN: 1945-7170
Titre abrégé: Endocrinology
Pays: United States
ID NLM: 0375040

Informations de publication

Date de publication:
01 11 2019
Historique:
received: 25 02 2019
accepted: 04 08 2019
pubmed: 10 8 2019
medline: 24 12 2019
entrez: 10 8 2019
Statut: ppublish

Résumé

Abiraterone acetate (AbiAc) inhibits tumor growth when administered to immunodeficient mice engrafted with the in vitro cell model of human adrenocortical carcinoma (ACC). Here, we developed and validated a zebrafish model engrafted with cortisol-secreting ACC cells to study the effects of AbiAc on tumor growth. The experimental conditions for AbiAc absorption in AB zebrafish embryos including embryo number, AbiAc concentration, and absorption time curve by liquid chromatography-tandem mass spectrometry were set up. The AbiAc effect on steroid production in AB zebrafish embryos was measured as well. ACC cells (the NCI-H295R cell line, the primary cell ACC29, and the negative control cell SW13) were treated with drug-induced liver injury fluorescent dye, and ∼240 cells per 4 nL was injected in the subperidermal space of the yolk sac of AB zebrafish embryos (n = 80 ± 10). The cell area was measured with Noldus DanioScopeTM software. AbiAc absorption in AB zebrafish embryos was stage dependent. Abiraterone (Abi) concentration decreased, whereas its main metabolite, Δ4A, increased. Accordingly, we demonstrated that zebrafish expressed mRNA encoding the enzyme 3β-hydroxysteroid dehydrogenase, which converts Abi in Δ4A. Furthermore, ABiAc reduced cortisol production and increased progesterone in zebrafish embryos. Three days after cell injection, the cortisol-secreting ACC cell area in solvent-treated embryos was significantly higher than that in 1 µM AbiAC‒treated embryos, whereas no AbiAc effect was observed in SW13 cells, which lack the Abi target enzyme CYP17A1.Zebrafish embryos xenografted with ACC tumor cells could be a useful, fast, and reproducible experimental model to preclinically test the activity of new drugs in human ACC.

Identifiants

pubmed: 31397841
pii: 5544841
doi: 10.1210/en.2019-00152
doi:

Substances chimiques

Antineoplastic Agents 0
Abiraterone Acetate EM5OCB9YJ6

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2620-2629

Informations de copyright

Copyright © 2019 Endocrine Society.

Auteurs

Alessandra Gianoncelli (A)

Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Michela Guarienti (M)

Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Martina Fragni (M)

Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Michela Bertuzzi (M)

Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Elisa Rossini (E)

Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Andrea Abate (A)

Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Ram Manohar Basnet (RM)

Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Daniela Zizioli (D)

Section of Biotechnology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Federica Bono (F)

Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Massimo Terzolo (M)

Department of Clinical and Biological Sciences, University of Turin, Internal Medicine 1, San Luigi Gonzaga Hospital, Orbassano, Italy.

Maurizio Memo (M)

Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Alfredo Berruti (A)

Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy.

Sandra Sigala (S)

Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH